StockNews.AI
JAGX
StockNews.AI
202 days

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

1. GLP-1 agonists have high GI adverse effects; Crofelemer improves these symptoms. 2. Napo filed a patent for Crofelemer to help with GLP-1 therapy side effects.

3m saved
Insight
Article

FAQ

Why Bullish?

Napo's patent filing for Crofelemer supports its development, potentially increasing JAGX's market value. Past approval of Crofelemer shows the potential for revenue growth.

How important is it?

The patent could significantly affect JAGX's positioning in a lucrative market, reflecting strong growth potential. Regulatory developments often result in substantial price impacts in biotech firms.

Why Long Term?

The patent could enhance Crofelemer's market position long-term, aiding JAGX's growth trajectory. It aligns with the expanding GLP-1 drug market.

Related Companies

JAGXMYTENPO
Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported in up to 85% Crofelemer, approved by the FDA under the brand name Mytesi® for HIV-related diarrhea, has demonstrated a significant benefit in improving gastrointestinal symptoms, including diarrhea, abdominal pain and discomfort, incontinence, bloating and constipation, when studied in populations with HIV-related diarrhea, cancer therapy-related diarrhea, and IBS Crofelemer could have a significant supportive impact on GLP-1 therapies, one of the fastest growing classes of drugs, estimated to be a $56 billion global market in 2025 and projected to grow at a CAGR of 21% to $322 billion 20341 SAN FRANCISCO, CA / ACCESS Newswire / January 29, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced Napo's filing of a broad defining provisional patent application with the U.S. Patent and Trademark Office (USPTO) for crofelemer, Jaguar's novel plant-based FDA-approved gastrointestinal normalizing prescription drug, to mitigate the gastrointestinal side effects associated with glucagon-like peptide-1 (GLP-1) receptor agonists and antagonists, together with other incretin-based therapies including glucose-dependent insulinotropic polypeptide (GIP) agonists and antagonists, and glucagon-agonist drugs. GLP-1 and GIP drugs are analogs for incretin hormones that are released by the gut and bind to receptors in the brain and gastrointestinal tract, suppressing appetite, which consequently leads to body weight loss.

Related News